during the first half of the year 
colonis had invested ahead of meaningful sales 
activity to support the launch of a number of 
products in the portfolio where we needed 
engagement with healthcare professionals.the business 
continues to consolidate its position as one of 
the leading suppliers of unlicensed imported 
medicines to the nhs.consequently the board took the decision to 
proceed with a closure plan for nupharm and 
trading ceased in january 2017. following  
an orderly closure process nupharm was 
placed into administration on 26 april 2017. 
nupharm’s results are included along with  
the impairment of its associated intangible 
assets and closure costs within the loss  
from discontinued operations of £13.7m  
(2016: £0.3m) shown in the consolidated 
income statement as it represents a separate 
major line of business.the statutory 
loss from continuing operations includes a 
number of non-recurring and non-operational 
costs associated with the transition to a more 
focused and simplified strategy that have  
been explained in the adjusted ebitda 
section on page 15.the group has a whistleblowing 
policy in place to cover both the whistle blower 
and the organisation, by showing a step-by-step 
process for raising and dealing with issues.at ulm, andrew 
guides a team of experts 
through the complex 
regulatory pathways and 
sales processes that 
impact the manufacture 
and supply of unlicensed 
medicines to the nhs.the board has established and maintains the group’s system of internal control.the board is responsible for assessing and reviewing its 
effectiveness.each potential material risk across the 
group is assessed against the likelihood of occurrence and the impact on the business, should the risk be realised.in addition to budgetary and profitability checks and balances, each proposed contract is reviewed 
from a legal perspective prior to being approved for signature.the group has a corporate social responsibility strategy and details of its activities in this area are set out on pages 24 and 25 of this 
annual report.principal risks and uncertainties 
the principal risks and uncertainties for the group are set out on pages 22 and 23 of the strategic report.at the annual general meeting of 
the company, to be held on 6 july 2017, each of the directors will be retiring and offering themselves for re-election in line with best practice.other than a notification on 2 may 2017 that slater investments reduced their shareholding to 2.47%, the company has not been informed of any 
changes to the above share interests between 31 march 2017 and the date of this report.the options are subject to performance targets measured over three financial years ending on 31 january 2019 with one third of the 
options capable of vesting each financial year.the options are exercisable on the later of 18 july 2019 and the date when the remuneration 
committee determines the extent to which the performance targets have been achieved.to the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company 
and the company’s members, as a body, for our audit work, for this report, or for the opinions we have formed.joint operations
where the group is a party to a joint operation, the consolidated financial statements include the group’s share of the joint operations assets and 
liabilities, as well as the group’s share of the entity’s profit or loss and other comprehensive income, on a line-by-line basis.trade and other receivables
trade and other receivables are recognised initially at fair value.the expenditure capitalised includes the cost of materials, direct labour 
and an appropriate proportion of overheads and capitalised borrowing costs.the grant date fair value of share-based payment 
awards granted is recognised as an employee expense with a corresponding increase in equity, over the period that the employees become 
unconditionally entitled to the awards.the amount recognised as an expense is adjusted to reflect the actual 
number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately 
recognised as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the 
vesting date.1.16 provisions
a provision is recognised in the balance sheet when the group has a present legal or constructive obligation as a result of a past event, that can 
be reliably measured and it is probable that an outflow of economic benefits will be required to settle the obligation.1.17 dividends
final dividends are recognised in the group’s financial statements as a liability in the period in which the dividends are approved by shareholders 
such that the company is obliged to pay the dividend.the group is assessing the impact of the amendments although does not anticipate  
it will have a material impact on the financial statements.for the less mature businesses, forecast revenues are based on management’s assessment of market trends and the impact of the 
group’s growth initiatives.the recoverable amount of these cash generating units has been calculated with reference to their value in use.management have used a pre-tax 
discount rate ranging from 8% to 10% that reflects current market assessments for the time value of money and the risks associated with the 
cgu.the fair value of all other options has been measured based on the black-scholes model.closure costs
the provision is management’s best estimate of costs to complete the orderly closure of nupharm laboratories limited, which was placed into 
administration on 26 april 2017.
rectification works
this provision was management’s best estimate of the further costs expected to be incurred in respect of the rectification work required as a result  
of nupharm laboratories limited being in mhra special measures at acquisition.the provision was partially utilised within the prior and current years, with the remaining amount released to the consolidated income statement, 
through discontinued operations, due to nupharm laboratories being discontinued.a) credit risk
credit risk is the risk of financial loss to the group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, 
and arises principally from the group’s receivables from customers.under section 408 of the companies act 2006 the company is exempt from the requirement to present its own income statement.